real-time news and commentary for investors
Wednesday, May 1
More on Covance (CVD): Q1 beats on all counts as total sales rose 9.3% Y/Y. Net profit jumped...
More on Covance (CVD): Q1 beats on all counts as total sales rose 9.3% Y/Y. Net profit jumped 35% on solid sales growth in its late-stage development business - which saw revenue grow by 17% - led by strength in its central laboratories and clinical development units. For the year, the company ups its EPS forecast to between $3 to $3.20 on revenue growth in the high-single digits. It previously had estimated earnings of around $2.85 to $3.15 and revenue growth in the mid-to-high single digits.